Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Sep 5;4(9):244.
doi: 10.1038/bcj.2014.64.

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

G Zugmaier  1 , M S Topp  2 , S Alekar  3 , A Viardot  4 , H-A Horst  5 , S Neumann  5 , M Stelljes  6 , R C Bargou  7 , M Goebeler  7 , D Wessiepe  8 , E Degenhard  1 , N Gökbuget  9 , M Klinger  1
Affiliations
Clinical Trial

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

G Zugmaier et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serum immunoglobulin levels over time in a phase 2 study of blinatumomab in patients with MRD-positive B-precursor acute lymphoblastic leukemia (ALL). Panels show data for serum IgM (a), IgG (b), IgA (c) and IgE (d) concentrations for five responders and one nonresponder (Patient 110–002, indicated with an asterisk).
See this image and copyright information in PMC

References

    1. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–977. - PubMed
    1. Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185–5187. - PubMed
    1. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498. - PubMed
    1. Murphy K. Janeway's Immunobiology. Vol 1. New York City: Garland Science - Taylor & Francis; 2011.
    1. van Tilburg CM, Bierings MB, Berbers GA, Wolfs TF, Pieters R, Bloem AC, et al. Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases. Pediatr Blood Cancer. 2012;58:701–707. - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources